Earlier today Anavex Life Sciences CEO Christopher Missling, PhD forwarded along an interesting post by Alberto Espay (someone I’ve followed for some time).
Despite 2 million MCI/dementia patients in Italy, the Italian National Institute of Health determined that the efficacy/safety axis of monoclonal antibodies is too undesirable, and vote strongly against administration for Alzheimer’s.
Notably, Anavex and Blarcamesine have recently (~30 days) seen interest from France (Audrey GABELLE), Poland (NeuroProtect/Dr. Maciej Czarnecki), Belgium, Netherlands, Luxembourg, Austria, Ireland (Beneluxa consortium) and various physicians and researchers from other European nations including the UK, Spain, and Germany.
A disease modifying therapy for Alzheimer’s that addresses very early pathogenesis is near. Cognitive, neurodegenerative, and plasma amyloid improvements are all superior to monoclonal antibodies with added safety benefit (no ARIA, no expensive monitoring), and rapid, oral availability.
New evidence for lifetime dementia incidence was recently published in Nature with damning implications for the American population. It cannot be permitted that Europe will soon be the only populace with an efficacious/safe Alzheimer’s therapy. I have taken it upon myself to send a letter to incoming FDA Commissioner Marty Makary M.D., M.P.H. requesting support in bringing this therapy to the American people so that we can hopefully soon join our friends in Europe.
Market Data 
Markets 
AI
